The intestinal microbiota determines the clinical efficacy of immune checkpoint blockers targeting PD-1/PD-L1. (3rd June 2018)

• Record Type: Journal Article
• Authors: Derosa, Lisa; Routy, Bertrand; Kroemer, Guido; Zitvogel, Laurence
• Is Part Of: Oncoimmunology. Volume 7:Number 6(2018)
• Publication Date: 2018-06-03
• Subjects: Microbiota -- immune checkpoint blockers -- PD-1/PD-L1 -- NSCLC -- RCC -- Biomarkers -- Inflammation and cancer -- New target; Tumors -- Immunological aspects -- Periodicals; Neoplasms -- therapy -- Periodicals; Immunotherapy -- Periodicals; 616.994
• DOI: 10.1080/2162402X.2018.1434468
• Languages: English
• ISSNs: 2162-402X

Abstract

ABSTRACT: Cancer immunotherapists have been searching for biomarkers predicting patient responses to PD-1/PD-L1 blockade in neoplastic cells as well as in the immune system. Now, accumulating evidence indicates that the composition of the intestinal microflora has a major impact on patient prognosis. Here, we enumerate the bacterial species that are associated with favorable outcome of immunotherapy.